Primary results from the phase 3 ALSYMPCA trial showed that radium-223 dichloride ( radium-223 ) , a targeted - emitter , improved overall survival compared with placebo and was well tolerated in patients with castration-resistant prostate cancer and symptomatic bone metastases .